Trials / Completed
CompletedNCT04883749
Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL
CLL-Frail - A Prospective, Multicenter Phase II Trial of Acalabrutinib in Very Old (≥80y) or Frail CLL-Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 53 (actual)
- Sponsor
- German CLL Study Group · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this trial is to show the efficacy, safety and feasibility of acalabrutinib in a cohort of CLL-patients ≥80 years or with a FRAIL scale score \>2 (5-item questionnaire to be filled out by the patient)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Acalabrutinib | Cycle (q28d): Acalabrutinib p.o.100 mg twice daily (BID) |
Timeline
- Start date
- 2021-06-01
- Primary completion
- 2025-05-08
- Completion
- 2025-05-08
- First posted
- 2021-05-12
- Last updated
- 2025-06-08
Locations
20 sites across 2 countries: Austria, Germany
Source: ClinicalTrials.gov record NCT04883749. Inclusion in this directory is not an endorsement.